Study S002300

A Non-interventional, Single-arm, Multicentre, Prospective Study Investigating the Glycaemic Control and Treatment Pattern Associated With the Use of Xultophy® (IDegLira) in a Real-world Adult Population With Type 2 Diabetes Mellitus in Japan. GOAL (Glycaemic Outcome Assessment IDegLira) Study

ClinicalTrials.gov record

Registration

Registration: NCT04838743
Acronym: GOAL
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 244
Start: 2021-04-23
Primary completion: 2022-10-26
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:IDegLira
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1253-2025; REGISTRY:jRCT1051210008

Registered primary outcomes

Change in local laboratory measured HbA1c (Glycated haemoglobin ) [From baseline (Visit 1) to 26 weeks (Visit 3)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.